Vanja Sikirica

4.4k total citations · 1 hit paper
100 papers, 3.0k citations indexed

About

Vanja Sikirica is a scholar working on Psychiatry and Mental health, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Vanja Sikirica has authored 100 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Psychiatry and Mental health, 16 papers in Surgery and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Vanja Sikirica's work include Attention Deficit Hyperactivity Disorder (50 papers), Pharmaceutical studies and practices (14 papers) and Child and Adolescent Psychosocial and Emotional Development (12 papers). Vanja Sikirica is often cited by papers focused on Attention Deficit Hyperactivity Disorder (50 papers), Pharmaceutical studies and practices (14 papers) and Child and Adolescent Psychosocial and Emotional Development (12 papers). Vanja Sikirica collaborates with scholars based in United States, United Kingdom and Canada. Vanja Sikirica's co-authors include M. Haim Erder, Paul Hodgkins, Jipan Xie, Mei Lü, Eric Q. Wu, Juliana Setyawan, Jennifer Kahle, Jalpa A. Doshi, James Signorovitch and Keith A. Betts and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and American Journal of Obstetrics and Gynecology.

In The Last Decade

Vanja Sikirica

95 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

2024 55 citations Dwight D. Koeberl, Andreas Schulze et al. Nature profile →

Peers

Countries citing papers authored by Vanja Sikirica

Since Specialization

Citations

This map shows the geographic impact of Vanja Sikirica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanja Sikirica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanja Sikirica more than expected).

Fields of papers citing papers by Vanja Sikirica

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanja Sikirica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanja Sikirica. The network helps show where Vanja Sikirica may publish in the future.

Co-authorship network of co-authors of Vanja Sikirica

This figure shows the co-authorship network connecting the top 25 collaborators of Vanja Sikirica. A scholar is included among the top collaborators of Vanja Sikirica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanja Sikirica. Vanja Sikirica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia breakdown → 2024 ·Nature ·Dwight D. Koeberl, Andreas Schulze, Neal Sondheimer, Gerald S. Lipshutz, Tarekegn Geberhiwot, Lerong Li, Rajnish Saini, Junxiang Luo, Vanja Sikirica, Ling Jin, M. Liang, (unknown), Stephanie Grünewald	55
2	A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases 2024 ·Orphanet Journal of Rare Diseases ·(unknown), (unknown), Geetanjoli Banerjee, Vanja Sikirica	8
3	EE699 Economic Burden of Propionic Acidemia by Age Stratum in the United States 2023 ·Value in Health ·Gargi Banerjee, Feng Mu, Ming‐Yuan Cheng, Erika M. Cook, Anan Zhang, (unknown), (unknown), Vanja Sikirica	0
4	Systematic literature review of the epidemiology of glycogen storage disease type 1a 2023 ·Journal of Pediatric Endocrinology and Metabolism ·Tamás Zelei, Sándor Kovács, Patrick F. Finn, (unknown), Vanja Sikirica, (unknown), Zoltán Vokó	1
5	Prevalence of Vitiligo among Children and Adolescents in the United States 2023 ·Dermatology ·Reema Patel, Amit G. Pandya, Vanja Sikirica, Kavita Gandhi, Shoshana Daniel, Kathryn Anastassopoulos, Yuji Yamaguchi, Lynne Napatalung, Rebecca Baik, Khaled Ezzedine	12
6	PSY6 Differences in All-Cause Health Care Costs of Alopecia Areata in the United States by Patient Subgroups: A Latent Class Approach 2021 ·Value in Health ·Nicolae Done, (unknown), Kunal K. Gandhi, Elyse Swallow, Weiping Gao, Vanja Sikirica, (unknown), Arash Mostaghimi	1
7	Symptoms and impacts in anemia of chronic kidney disease 2020 ·Journal of Patient-Reported Outcomes ·Susan D. Mathias, Steven I. Blum, Vanja Sikirica, Kirsten L. Johansen, Hilary H. Colwell, (unknown)	19
8	Treatment patterns among adults with ADHD receiving long-acting therapy. 2018 ·PubMed ·Zhou Zhou, Zheng‐Yi Zhou, (unknown), Vanja Sikirica, Jipan Xie, Regina Grebla	1
9	Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study 2017 ·Neurology and Therapy ·Vanja Sikirica, Per Gustafsson, Charles Makin	2
10	Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison 2017 ·European Child & Adolescent Psychiatry ·Alain Joseph, Rajeev Ayyagari, Meng Xie, (unknown), Jipan Xie, Michael Huß, Vanja Sikirica	25
11	Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD 2017 ·Journal of Attention Disorders ·David Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huß	18
12	The Caregiver Perspective on Paediatric ADHD (CAPPA) survey: Understanding sociodemographic and clinical characteristics, treatment use and impact of ADHD in Europe 2016 ·Journal of Affective Disorders ·Emuella Flood, Kavita Gajria, Vanja Sikirica, Camila Dietrich, (unknown), Valerie Harpin, Tobias Banaschewski, Javier Quintero, M. Haim Erder, Moshe Fridman, Kristina Chen	20
13	Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine 2016 ·Patient Preference and Adherence ·Alain Joseph, Martin Cloutier, Annie Guérin, Roy Nitulescu, Vanja Sikirica	3
14	Systematic Literature Review and Mixed Treatment Comparison of Gxr Versus other Treatments in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) 2014 ·Value in Health ·Alain Joseph, Rajeev Ayyagari, Matthias Bischof, (unknown), Meng Xie, (unknown), Vanja Sikirica	4
15	Immediate-Release Versus Extended-Release Guanfacine for Treatment of Attention-Deficit/Hyperactivity Disorder 2013 ·The American Journal of Managed Care ·Vanja Sikirica, Jipan Xie, (unknown), M. Haim Erder, Paul Hodgkins, Hongbo Yang, (unknown), (unknown)	6
16	Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents 2012 ·PharmacoEconomics ·Vanja Sikirica, M. Haim Erder, Jipan Xie, Dendy Macaulay, (unknown), Paul Hodgkins, Eric Q. Wu	23
17	Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States 2012 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Jalpa A. Doshi, Paul Hodgkins, Jennifer Kahle, Vanja Sikirica, Michael J. Cangelosi, Juliana Setyawan, M. Haim Erder, Peter J. Neumann	338
18	Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research 2012 ·Value in Health ·James Signorovitch, Vanja Sikirica, M. Haim Erder, Jipan Xie, Mei Lü, Paul Hodgkins, Keith A. Betts, Eric Q. Wu	310
19	PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS 2011 ·Value in Health ·M. Haim Erder, (unknown), E.Q. Wu, P. Hodgkins, Vanja Sikirica	1
20	Patient-Controlled Analgesia-Related Medication Errors in the Postoperative Period 2009 ·Drug Safety ·Jeff Schein, Rodney W. Hicks, Winnie W. Nelson, Vanja Sikirica, D. John Doyle	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact